NASDAQ · NUVL
Nuvalent, Inc.
Healthcare · Biotechnology
$123.960.00% ($0.00)at close
As of 9:30 AM ET
Market cap
$9.13B
P/E
N/M
EPS (TTM)
-$5.72
Next earnings
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $123.96 · Price Jul 15, 1:30 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The latest financial period used here ended about 7 months ago, so a newer report is probably out. Metrics shown may not reflect it.
What changed
The stock rose 50.33% over the last year. Free cash flow declined 53.48% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or free cash flow over the next period would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
8
Buy
11
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Aug 6, 2026
Q2 FY26 · EPS est -$1.44 · Revenue est $245.5K
Q1 FY26
Reported May 7, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$1.39
Estimate
-$1.35
Year over year
n/m
Vs prior quarter
n/m
1 beat · 3 misses in the last 4 quarters
Institutional Sentiment
Nuvalent, Inc. · NUVL
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.